Literature DB >> 23959317

Improving the lethal effect of cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module.

Roberto Díez-Martínez1, Héctor D de Paz, Héctor de Paz, Noemí Bustamante, Ernesto García, Margarita Menéndez, Pedro García.   

Abstract

Phage endolysins are murein hydrolases that break the bacterial cell wall to provoke lysis and release of phage progeny. Recently, these enzymes have also been recognized as powerful and specific antibacterial agents when added exogenously. In the pneumococcal system, most cell wall associated murein hydrolases reported so far depend on choline for activity, and Cpl-7 lysozyme constitutes a remarkable exception. Here, we report the improvement of the killing activity of the Cpl-7 endolysin by inversion of the sign of the charge of the cell wall-binding module (from -14.93 to +3.0 at neutral pH). The engineered variant, Cpl-7S, has 15 amino acid substitutions and an improved lytic activity against Streptococcus pneumoniae (including multiresistant strains), Streptococcus pyogenes, and other pathogens. Moreover, we have demonstrated that a single 25-μg dose of Cpl-7S significantly increased the survival rate of zebrafish embryos infected with S. pneumoniae or S. pyogenes, confirming the killing effect of Cpl-7S in vivo. Interestingly, Cpl-7S, in combination with 0.01% carvacrol (an essential oil), was also found to efficiently kill Gram-negative bacteria such as Escherichia coli and Pseudomonas putida, an effect not described previously. Our findings provide a strategy to improve the lytic activity of phage endolysins based on facilitating their pass through the negatively charged bacterial envelope, and thereby their interaction with the cell wall target, by modulating the net charge of the cell wall-binding modules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959317      PMCID: PMC3811316          DOI: 10.1128/AAC.01372-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2007-03-23

Review 2.  Enzybiotics: a look to the future, recalling the past.

Authors:  Patricia Veiga-Crespo; José Manuel Ageitos; Margarita Poza; Tomás G Villa
Journal:  J Pharm Sci       Date:  2007-08       Impact factor: 3.534

Review 3.  Taking aim on bacterial pathogens: from phage therapy to enzybiotics.

Authors:  Juan A Hermoso; José L García; Pedro García
Journal:  Curr Opin Microbiol       Date:  2007-09-27       Impact factor: 7.934

4.  LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae.

Authors:  David G Pritchard; Shengli Dong; Marion C Kirk; Robert T Cartee; John R Baker
Journal:  Appl Environ Microbiol       Date:  2007-09-28       Impact factor: 4.792

5.  Insights into the structure-function relationships of pneumococcal cell wall lysozymes, LytC and Cpl-1.

Authors:  Begoña Monterroso; José Luis Sáiz; Pedro García; José Luis García; Margarita Menéndez
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

Review 6.  Bacteriophage lysins as effective antibacterials.

Authors:  Vincent A Fischetti
Journal:  Curr Opin Microbiol       Date:  2008-10-14       Impact factor: 7.934

7.  Purified recombinant phage lysin LySMP: an extensive spectrum of lytic activity for swine streptococci.

Authors:  Y Wang; J H Sun; C P Lu
Journal:  Curr Microbiol       Date:  2009-03-07       Impact factor: 2.188

8.  Mass spectrometric characterization of glycated beta-lactoglobulin peptides derived from galacto-oligosaccharides surviving the in vitro gastrointestinal digestion.

Authors:  F Javier Moreno; Jesús Eduardo Quintanilla-López; Rosa Lebrón-Aguilar; Agustín Olano; María Luz Sanz
Journal:  J Am Soc Mass Spectrom       Date:  2008-04-10       Impact factor: 3.109

Review 9.  Novel approaches to fight Streptococcus pneumoniae.

Authors:  Beatriz Maestro; Jesús M Sanz
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2007-11

10.  Fpocket: an open source platform for ligand pocket detection.

Authors:  Vincent Le Guilloux; Peter Schmidtke; Pierre Tuffery
Journal:  BMC Bioinformatics       Date:  2009-06-02       Impact factor: 3.169

View more
  36 in total

1.  Linker Editing of Pneumococcal Lysin ClyJ Conveys Improved Bactericidal Activity.

Authors:  Hang Yang; Dehua Luo; Irina Etobayeva; Xiaohong Li; Yujing Gong; Shujuan Wang; Qiong Li; Poshi Xu; Wen Yin; Jin He; Daniel C Nelson; Hongping Wei
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

3.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia.

Authors:  Rolf Lood; Assaf Raz; Henrik Molina; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

5.  Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.

Authors:  Assaf Raz; Anna Serrano; Anaise Hernandez; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

6.  Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model.

Authors:  Rolf Lood; Benjamin Y Winer; Adam J Pelzek; Roberto Diez-Martinez; Mya Thandar; Chad W Euler; Raymond Schuch; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

7.  Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.

Authors:  Bruno Corsini; Roberto Díez-Martínez; Leire Aguinagalde; Fernando González-Camacho; Esther García-Fernández; Patricia Letrado; Pedro García; Jose Yuste
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 8.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

Review 9.  Enzybiotics: Enzyme-Based Antibacterials as Therapeutics.

Authors:  Dorien Dams; Yves Briers
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 10.  Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.

Authors:  Patrizia Ferraboschi; Samuele Ciceri; Paride Grisenti
Journal:  Antibiotics (Basel)       Date:  2021-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.